Overview

A Phase II Study of AT7519M, a CDK Inhibitor, in Patients With Relapsed and/or Refractory Chronic Lymphocytic Leukemia

Status:
Completed
Trial end date:
2015-02-13
Target enrollment:
Participant gender:
Summary
The purpose of this study is to find out what effects a new drug AT7519M has on chronic lymphocytic leukemia.
Phase:
Phase 2
Details
Lead Sponsor:
NCIC Clinical Trials Group
Collaborators:
Astex Pharmaceuticals
Astex Pharmaceuticals, Inc.